Vir director sells 22,000 shares in 10b5-1 plan

Vir Biotechnology director Vicki L. Sato reported selling 22,000 shares of common stock in open-market transactions.

Accepted by SEC EDGAR 03/03/2026 - 12:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vir Biotechnology director Vicki L. Sato reported selling 22,000 shares of common stock in open-market transactions. The sales occurred on March 2, 2026 at weighted average prices of $9.5039 and $9.98 per share under a pre-arranged Rule 10b5-1 trading plan. After these sales, she directly owned 1,122,391 shares.

Insider Trade Summary

Net Seller: 22,000 shares

Net Sell 2 txns

Insider SATO VICKI L

Role Director

Sold 22,000 shs ($209K)

Type	Security	Shares	Price	Value
Sale	Common Stock	21,800	$9.5039	$207K
Sale	Common Stock	200	$9.98	$2K

Holdings After Transaction: Common Stock — 1,122,391 shares (Direct)

Footnotes (3)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vir Biotechnology (VIR) director Vicki L. Sato report on this Form 4?

Director Vicki L. Sato reported selling 22,000 shares of Vir Biotechnology common stock. The transactions were open-market sales executed on March 2, 2026 and were conducted under a pre-established Rule 10b5-1 trading plan adopted earlier.

How many Vir Biotechnology (VIR) shares did Vicki L. Sato sell and at what prices?

Vicki L. Sato sold 22,000 shares of Vir Biotechnology common stock. Weighted average prices were $9.5039 for 21,800 shares and $9.98 for 200 shares, with actual trade prices ranging within specified price bands disclosed in the footnotes.

When did the reported Vir Biotechnology (VIR) insider sales take place?

The reported insider sales took place on March 2, 2026. On that date, director Vicki L. Sato executed two open-market transactions in Vir Biotechnology common stock totaling 22,000 shares, as detailed in the Form 4 filing and accompanying footnotes.

How many Vir Biotechnology (VIR) shares does Vicki L. Sato own after these sales?

Following the reported sales, Vicki L. Sato directly owns 1,122,391 shares of Vir Biotechnology common stock. This post-transaction ownership figure is disclosed in the Form 4, reflecting her holdings after the 22,000 shares were sold in the open market.

Were Vicki L. Sato’s Vir Biotechnology (VIR) sales part of a 10b5-1 trading plan?

Yes, the sales were executed under a Rule 10b5-1 trading plan. The footnotes state the plan was adopted on March 27, 2025, indicating the transactions were pre-arranged according to this preset trading program for systematic share sales.

How were the Vir Biotechnology (VIR) sale prices structured in these transactions?

The Form 4 reports weighted average prices for the sales. For the 21,800-share sale, trades occurred between $8.97 and $9.91. For the 200-share sale, trades occurred between $9.97 and $9.99, with detailed breakdowns available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SATO VICKI L

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		21,800	D	$9.5039(2)	1,122,591	D
Common Stock	03/02/2026		S(1)		200	D	$9.98(3)	1,122,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.